Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

44.12USD
1:38am IST
Price Change (% chg)

$0.31 (+0.71%)
Prev Close
$43.81
Open
$43.81
Day's High
$44.27
Day's Low
$43.77
Volume
138,009
Avg. Vol
217,988
52-wk High
$49.10
52-wk Low
$35.77

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.95
Market Cap (Mil.): $92,795.55
Shares Outstanding (Mil.): 2,112.56
Dividend: 0.83
Yield (%): 1.90

Financials

  NVO.N Industry Sector
P/E (TTM): 27.34 37.83 38.47
EPS (TTM): 1.60 -- --
ROI: 65.79 18.99 18.25
ROE: 71.98 19.75 19.13
Search Stocks

Novo Nordisk gets positive opinion on Tresiba for children in Europe

COPENHAGEN - Drug maker Novo Nordisk said the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of its diabetes drug Tresiba for the treatment of children and adolescents.

19 Dec 2014

Novo Nordisk gets positive opinion on Tresiba for children in Europe

COPENHAGEN, Dec 19 - Drug maker Novo Nordisk said the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of its diabetes drug Tresiba for the treatment of children and adolescents.

19 Dec 2014

BRIEF-Per Aarsleff to build shell structure for Novo Nordisk

* Has entered into a partnering contract with Novo Nordisk A/S to build a shell structure with a total gross area of 15,000 square metres

04 Dec 2014

UPDATE 1-Bayer to seek approval for haemophilia drug this month

* Bay 81-8973 is based on Bayer's established Kogenate drug

02 Dec 2014

NORDIC STOCKS - Factors to watch on Nov 25

OSLO, Nov 25 - The following stocks may be affected by newspaper reports and other factors on Tuesday:

25 Nov 2014

BRIEF-Novo Nordisk has reduced the number of executives to six

COPENHAGEN, Nov 25 - Novo Nordisk A/S : ** Has reduced the number of executives from seven to six ** Executive vice president and chief of staffs Lise Kingo has decided to leave Novo Nordisk

25 Nov 2014

BRIEF-Novo'S victoza receives positive opinion for use in adults with type 2 diabetes

COPENHAGEN, Nov 21 - Novo Nordisk A/S : ** Victoza receives positive Committee for Medicinal Products for Human Use opinion opinion for use in adults with type 2 diabetes and moderate renal impairment ** Once the European Commission approves the label expansion, physician s in the European Union will be able to prescribe Victoza, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments

21 Nov 2014

BRIEF-Nine out of 10 lost weight with Novo's obesity drug -study

Nov 4 - Novo Nordisk A/S says: * New phase 3a data demonstrate that nine out of 10 adults with obesity lost

04 Nov 2014

BRIEF-Novo Nordisk invests $130 mln in diabetes research in Denmark

* Invests 750 million Danish crowns in new laboratories for diabetes research in Denmark (around $130 million)

31 Oct 2014

UPDATE 3-Novo Nordisk reassures on 2015 outlook after Sanofi jolt

* Shares up almost 4 percent (Adds analysts, details on Tresiba, updates shares)

30 Oct 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €75.22 --
Eli Lilly and Co (LLY.N) $71.42 -0.98

Earnings vs. Estimates

Search Stocks